People
The People
Governance grade: B. A fully refreshed, independent board and a new-generation CEO executing a credible turnaround strategy, offset by negligible insider ownership and a legacy of governance scandals under prior management that required activist intervention to fix.
The People Running This Company
Centene's leadership was rebuilt from the ground up after activist Politan Capital forced a board overhaul and the exit of 25-year CEO Michael Neidorff in 2022. The current team is executing a "value over volume" strategy focused on margin recovery, portfolio simplification, and debt reduction.
London has been CEO for four years through an extremely difficult operating environment: Medicaid redeterminations, marketplace volatility, a $6.7B goodwill impairment, and a stock that fell from $64 to $25 in 2025. Her response has been disciplined: aggressive repricing, ABA fraud detection, Magellan divestiture, and SG&A cuts. She bought 19,230 shares at $25.50 in August 2025 near the 52-week low — a meaningful signal. The April 2026 executive restructure (adding Finke and Carson as group presidents) adds experienced operational depth for the next phase.
What They Get Paid
CEO Total Comp ($M)
Cash Salary %
Equity & Bonus %
London's $20.6M total compensation is 93% equity-linked, which is structurally well-aligned. A portion of her stock options carry an exercise price of $81.85 with a performance condition requiring 20 consecutive trading days above $100 — meaning those options are currently deeply underwater at ~$42 per share. This is genuinely at-risk pay tied to shareholder outcomes.
For context, her predecessor Neidorff earned nearly $25M in 2020, making him the highest-paid healthcare executive in the US at a time when governance was deteriorating. London's pay package is comparable in size but far better structured, with most value locked in equity that only pays out if the stock recovers.
The CFO's base salary of $975K with a 100% bonus target is reasonable for a company of this scale ($175B revenue). Without the full proxy detail on Named Executive Officers, a comprehensive peer comparison is limited, but the structure is appropriate for managed care.
Are They Aligned?
Capital allocation behavior tells a more positive alignment story than raw ownership. In FY2024, management repurchased 42 million shares for $3B — a meaningful capital return when shares traded in the $60s-$70s. The 2025 pivot to debt reduction ($189M in Q4, debt-to-capital to 46.5%) and the Magellan divestiture show discipline over ego: management chose balance sheet health over headline buyback numbers when the business hit headwinds.
Smart money is loading up. David Einhorn's Greenlight Capital grew its position to 2.6M shares by Q4 2025, up 70% quarter-over-quarter. Robeco increased its stake by 427%. The institutional base sees the earnings recovery thesis.
Related-party behavior: The current board and management are clean on related-party transactions. The legacy issues — the shareholder derivative suit alleging Health Net acquisition overpayment and Neidorff-era governance — have been resolved through the board overhaul. No new related-party red flags have surfaced under current leadership.
Skin-in-the-Game Score (1-10)
Low ownership (0.31%) is the primary drag. Offset by CEO open-market buy at lows, deeply underwater performance options, disciplined capital allocation pivot, and clean related-party record.
Board Quality
Board Size
Independent Directors
Independence %
What works: The board is genuinely refreshed — 6 of 9 directors joined in 2020-2022 as part of the Politan-driven overhaul. Chairman Eppinger is separated from the CEO, a structural improvement over the Neidorff era. The expertise mix covers insurance operations (Eppinger), audit (Blume), managed care (Burdick), CFO experience (Coughlin, Tanji), healthcare ops (Dallas), and technology (Ford). Two directors (Coughlin, Tanji) bring deep CFO-level financial oversight.
What is missing: No director has deep Medicaid policy or government affairs expertise — notable for a company whose largest segment is government-sponsored healthcare. No physician or clinical leader on the board, which is unusual for a company managing care for 28M+ members. Board gender diversity improved to 2 of 9 women (22%) but remains below best-practice targets.
Legacy governance context: This board exists because governance under Neidorff failed. Politan Capital took a $900M stake in late 2021 and forced a complete restructuring: five new directors, CEO exit, board declassification, and a Value Creation Plan. Centene also settled PBM overcharge claims with multiple states totaling over $236M (California $215M, New Hampshire $21M). The House Judiciary Committee has subpoenaed ACA insurers including Centene as part of an Obamacare subsidy fraud investigation — an ongoing regulatory risk. These are legacy issues, but they inform the governance risk premium the stock still carries.
The Verdict
Governance Grade
Strongest positives: Board completely overhauled post-activist intervention with genuine independence (89%). CEO bought shares at 52-week lows. Compensation is 93% equity-linked with demanding performance hurdles. Capital allocation pivoted from buybacks to balance sheet repair when conditions warranted. Magellan divestiture shows willingness to simplify.
Real concerns: Insider ownership at 0.31% is extremely low for a $20B company — management has limited personal wealth at risk. The company carries legacy reputational damage from multi-state PBM fraud settlements and the Neidorff-era governance failures. An active Congressional investigation into ACA subsidies adds regulatory tail risk. Board lacks clinical and government policy expertise for a company that is fundamentally a government healthcare contractor.
What would cause an upgrade: Meaningful insider buying beyond London's single purchase — particularly from the CFO or new group presidents. Resolution of the Congressional ACA investigation without material findings. Sustained earnings recovery (the more-than-$3 EPS guide for 2026 is a start) proving the turnaround strategy works. Addition of a director with deep Medicaid/government policy experience.
What would cause a downgrade: Material adverse findings from the Congressional ACA investigation. Resumption of aggressive buybacks before the balance sheet is fully repaired. Executive departures during the critical turnaround period. New related-party or compliance issues under current management.